CD33 and acute myeloid leukemia: Clinical trials are ongoing to evaluate the potential benefit of infusing CAR-NK cells in patients with CD7+ AML (clinicaltrials.gov Identifier: NCT02742727) and CD33 or CD123-expressing AML (Table 1).